Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib

Nature Methods

Volumn 2, Issue 5, 2005, Pages 357-362

  Berkers, Celia R ^a,b   Verdoes, Martijn ^a,d   Lichtman, Eben ^a   Fiebiger, Edda ^a   Kessler, Benedikt M ^a   Anderson, Kenneth C ^a   Ploegh, Hidde L ^a   Ovaa, Huib ^a,b   Galardy, Paul J ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; DIPEPTIDE DERIVATIVE; PROTEASOME; PROTEASOME INHIBITOR; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; LEUPEPTIN; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ACCURACY; ANIMAL CELL; ARTICLE; CELL ASSAY; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG APPROVAL; DRUG MECHANISM; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MULTIPLE MYELOMA; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; UNITED STATES; ANIMAL; DRUG EFFECT; MOUSE; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; HUMANS; LEUPEPTINS; MICE; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 18244406798     PISSN: 15487091     EISSN: None     Source Type: Journal    
DOI: 10.1038/nmeth759     Document Type: Article

References (25)

1. Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071-3076 (2001).
2. Rock, K.L. & Goldberg, A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17, 739-797 (1999).
3. Glickman, M.H. & Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373-428 (2002).
4. Kisselev, A.F. & Goldberg, A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8, 739-758 (2001).
5. Adams, J. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622 (1999).
6. Dahlmann, B., Ruppert, T., Kloetzel, P.M. & Kuehn, L. Subtypes of 20S proteasomes from skeletal muscle. Biochimie 83, 295-299 (2001).
7. Driscoll, J., Brown, M.G., Finley, D. & Monaco, J.J. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 365, 262-264 (1993).
8. Gaczynska, M., Rock, K.L. & Goldberg, A.L. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 365, 264-267 (1993).
9. Bogyo, M. et al. Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc. Natl Acad. Sci. USA 94, 6629-6634 (1997).
10. Greenbaum, D., Medzihradszky, K.F., Burlingame, A. & Bogyo, M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem. Biol. 7, 569-581 (2000).
11. Liu, Y., Patricelli, M.P. & Cravatt, B.F. Activity-based protein profiling: the serine hydrolases. Proc. Natl. Acad. Sci. USA 96, 14694-14699 (1999).
12. Adam, G.C., Cravatt, B.F. & Sorensen, E.J. Profiling the specific reactivity of the proteome with non-directed activity-based probes. Chem. Biol. 8, 81-95 (2001).
13. Adam, G.C., Sorensen, E.J. & Cravatt, B.F. Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype. Nat. Biotechnol. 20, 805-809 (2002).
14. Kessler, B.M. et al. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem. Biol. 8, 913-929 (2001).
15. Ovaa, H. et al. Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy. Angew. Chem. Int. Edn. Engl. 42, 3626-3629 (2003).
16. Dantuma, N.P., Lindsten, K., Glas, R., Jellne, M. & Masucci, M.G. Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat. Biotechnol. 18, 538-543 (2000).
17. Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071-3076 (2001).
18. Bogyo, M., Shin, S., McMaster, J.S. & Ploegh, H.L. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem. Biol. 5, 307-320 (1998).
19. Garcia-Echeverria, C. Recent advances in the identification and development of 20S proteasome inhibitors. Mini Rev. Med. Chem. 2, 247-259 (2002).
20. Lightcap, E.S. et al. Proteasome inhibition measurements: clinical application. Clin. Chem. 46, 673-683 (2000).
21. Stein, R.L., Melandri, F. & Dick, L. Kinetic characterization of the chymotryptic activity of the 20S proteasome. Biochemistry 35, 3899-3908 (1996).
22. Fiebiger, E., Story, C., Ploegh, H.L. & Tortorella, D. Visualization of the ER-to-cytosol dislocation reaction of a type I membrane protein. EMBO J. 21, 1041-1053 (2002).
23. Lindsten, K., Menendez-Benito, V., Masucci, M.G. & Dantuma, N.P. A transgenic mouse model of the ubiquitin/proteasome system. Nat. Biotechnol. 21, 897-902 (2003).
24. Luker, G.D., Pica, C.M., Song, J., Luker, K.E. & Piwnica-Worms, D. Imaging 26S proteasome activity and inhibition in living mice. Nat. Med. 9, 969-973 (2003).
25. Elliott, P.J., Soucy, T.A., Pien, C.S., Adams, J. & Lightcap, E.S. Assays for proteasome inhibition. Methods Mol. Med. 85, 163-172 (2003).